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Nicotinamide N-methyltransferase (NNMT) is responsible for the N-methylation of nicotinamide 
to 1-methylnicotinamide. Our recent studies have demonstrated that NNMT regulates cellular 
processes fundamental to the correct functioning and survival of the cell. It has been proposed 
that NNMT may possess β-carboline N-methyltransferase activity, endogenously and 
exogenously-produced pyridine-containing compounds which, when N-methylated, are potent 
inhibitors of Complex I and have been proposed to have a role in the pathogenesis of Parkinson’s 
disease. We have investigated the ability of recombinant NNMT to N-methylate norharman to 2-
N-methylnorharman. In addition, we have investigated the toxicity of the β-carboline norharman, 
its precursor 1,2,3,4-tetrahydronorharman and its N-methylated metabolite 2-N-
methylnorharman, using our in vitro SH-SY5Y NNMT expression model. Recombinant NNMT 
demonstrated norharman 2N-methyltransferase activity, with a Km of 90 ± 20 µM, a kcat of 3 x 10-
4
 ± 2 x 10-5 s-1 and a specificity constant (kcat/Km) of 3 ± 1 s-1 M-1. 1,2,3,4-Tetrahydronorharman 
was the least toxic of all three compounds investigated, whereas norharman demonstrated the 
greatest, with no difference observed in terms of cell viability and cell death between NNMT-
expressing and non-expressing cells. In NNMT-expressing cells, 2-N-methylnorharman 
increased cell viability and cellular ATP concentration in a dose-dependent manner after 72 and 
120 h incubation, an effect which was not observed after 24 h incubation or in non-NNNT-
expressing cells at any time point. Taken together, these results suggest that NNMT may be a 
detoxification pathway for β-carbolines such as norharman. 
 
SUMMARY STATEMENT 
Nicotinamide N-methyltransferase has the ability to N-methylate the endogenously-produced β-
carboline norharman, resulting in the production of 2-N-methylnorharman which demonstrated 
significantly lower toxicity in vitro. 
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Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to 1-
methylnicotinamide (MeN) using S-adenosylmethionine (SAM) as cofactor [1]. It is widely 
expressed in human tissues, most strongly in the liver [2] and is upregulated in numerous cancers 
[3-6]. In the human brain, NNMT expression varies between regions and occurs solely in 
neurones, in particular within the dopaminergic neurones of the substantia nigra (SN) [2]. 
NNMT expression is also significantly elevated in the brains of patients who have died of 
Parkinson’s disease (PD) [2,7]. Stable expression of recombinant NNMT in SH-SY5Y human 
neuroblastoma cells, which have no endogenous expression of NNMT, increases both Complex I 
(CxI) activity and ATP synthesis [8], and promotes neurite branching and the formation of 
synapses via the activation of the Akt & ephrin B2 signalling pathways [9]. NNMT expression 
also protects against the toxicity of a variety of PD-relevant mitotoxins such as MPP+, rotenone 
and 6-hydroxydopamine [8,10]. These effects are replicated by MeN [8-10], suggesting that 
increased MeN production mediated the effects of NNMT.  
 
A number of studies have proposed that NNMT has the ability to N-methylate both endogenous 
and exogenous compounds, for example tetrahydroisoquinolines and β-carbolines (BCs), thereby 
generating inhibitors of CxI [2,11,12]. BCs are found endogenously within the brain, where they 
arise from tryptamine metabolism [13,14], and as constituents/breakdown products in well-
cooked foods such as meat and fish, roasted coffee, and tobacco smoke [15]. Due to the 
combination of their relatively high hydrophobicity and charge at physiological pH, BCs readily 
cross the blood-brain-barrier, whereupon they are N-methylated by as-yet unidentified N-
methyltransferases [13,16,17]. They are considered to be possible mediators of SN degeneration 
because of their resemblance to 1-methyl-4-phenylpyridinium ion (MPP+) and their ability to 
inhibit CxI [18-23]. Stereotaxic injection of BCs and their methylated derivatives into either the 
SN or the median forebrain bundle of rats resulted in striatal dopamine depletion, nigral lesions 
and gliosis [18,22,24] along with the onset of Parkinsonian-like motor symptoms [25]. In 
addition, the levels of BCs such as norharman (NH) have been shown to be elevated in the 
cerebral spinal fluid and SN of PD patients [24,26]. NH is a prototypical BC produced 
endogenously in the brain from 1,2,3,4-tetrahydronorharman (THNH) [27], which itself is 
produced via the demethylation of 1-methylTHNH [14,27,28]. The pyridine nitrogen of NH 
undergoes methylation to produce 2-N-methylnorharman (MeNH) [16] (Figure 1). MeNH is 
taken up selectively into dopaminergic neurones via the dopamine transporter (DAT) [23], where 
it weakly inhibits CxI [11,18,29]. The toxicity of MeNH is increased by its subsequent N-
methylation to 2,9-dimethylnorharman (DMeNH), the toxicity of which is reported to be 
comparable to that of MPP+ [20]. The concentration of DMeNH has been shown to be elevated 
in the cerebral spinal fluid of PD patients [21-23]. 
 
The identity of the enzymes responsible for these N-methylation reactions remains unknown. 
Gearhart et al. [30] demonstrated that phenylethanolamine N-methyltransferase (PNMT) has 2N-
methyltransferase activity towards 9-N-methylnorharman, but 9-N-methylnorharman does not 
occur naturally within the brain. Therefore, the physiological relevance of this is unclear. No 
enzyme has been identified as being responsible for the initial 2-N-methylation of NH or for the 
subsequent 9-N-methylation to DMeNH. Several studies have suggested that NNMT may have 
NH 2N-methyltransferase activity and thus initiate the production of toxic N-methylated 
derivatives [2,7,31]. Although NNMT has been shown to be capable of N-methylating a variety 
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of non-physiological substrates [32], as yet there is no direct experimental evidence to 
demonstrate BC N-methyltransferase activity for NNMT. If NNMT does possess NH 2N-
methyltransferase activity, it is possible that NNMT may increase the toxicity of NH, and as such 
may provide a mechanistic link between elevated NNMT expression and PD pathology.  
 
To test this hypothesis, we assessed whether recombinant human NNMT possessed NH 2N-
methyltransferase activity and compared the toxicity of THNH, NH and MeNH using our in vitro 
NNMT expression model.  
 
EXPERIMENTAL PROCEDURES 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich (Poole, UK) and were 
of the highest grade available. Cell culture reagents were purchased from Life Technologies 
(Paisley, UK). 
 
Synthesis of 2-N-methylnorharman 
The synthesis of MeNH was based upon the method of Thatcher et al. [33]. Briefly, 500 mg NH 
were stirred with 10 mL acetonitrile (Fisher Scientific, Lougborough, UK) for 30 mins at RT, 
after which 0.5 mL methyl iodide were added and the reaction stirred at RT for 16 hours. The 
precipitate was filtered, washed with 5 mL diethyl ether three times, and dried under vacuum. A 
light yellow solid was obtained in a yield of 90%. A melting point of 236 – 238 oC was 
consistent with that previously reported [34]. 1H-NMR spectrum (400 MHz (DMSO d6)): δ 12.78 
(1H, s, NH), 9.36 (1H, s, aromatic), 8.81 (1H, s, aromatic), 8.65 (1H, s, aromatic), 8.50 (1H, s, 
aromatic), 7.80 (2H, s, aromatic), 7.46 (1H, s, aromatic), 4.49 (3H, s, N+CH3). 13C-NMR 
spectrum (100 MHz (DMSO d6)): δ 143.9, 134.8, 134.8, 133.4, 131.87, 123.6, 121.5, 119.2, 
117.6, 113.0, 47.7 (N+CH3). Both NMR spectra matched those reported by Thatcher et al. [33]. 
m/z MeNH: 183.1 (C12H11N2+).  
 
Investigation of NNMT norharman 2N-methyltransferase activity 
Cloning, expression and purification of recombinant human NNMT 
Total RNA was isolated from normal human renal tissue using the SV Total RNA Isolation Kit 
(Promega, Madison, WI, USA) as per previously described [6]. Total RNA (2µg) was reverse-
transcribed into cDNA using M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) 
using random primers. cDNA was subjected to PCR using the primers 5’-
TCACATATGGAATCAGGCTTCA-3’ (forward) and 5’-CTAAAGCTTTCACAGGGGTCTG-
3’ (reverse) to amplify the human NNMT open reading frame which was cloned into a pET-28a 
plasmid vector to obtain the expression construct pET-28a-wt-hNNMT. This was transformed 
into E. Coli BL21 (DE3). Recombinant wild-type human NNMT (hNNMTWT) was isolated from 
IPTG-induced cells and purified to homogeneity using nickel affinity purification as previously 
described [35]. Purity was confirmed using SDS-PAGE/Coomassie blue staining and NNMT 
identity was confirmed using SDS-PAGE/Western blotting as outlined in Table S1. Enzyme 
activity was 6740 nmoles 1-methylnicotinamide produced/h/mg protein. 
 
Determination of MeNH and THNH parent-to-product ion transitions 
The ability of NNMT to 2-N-methylate NH was assessed using a modification of our previously-
described NNMT assay [36]. To take into account the possibility that the amount of MeNH 
produced was below the limit of detection for the assay, HPLC-UV detection of MeNH was 
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replaced with LC-MS/MS detection. To identify parent-to-product ion (PtPI) transitions for 
MeNH and THNH (internal standard), 1 µg/mL in 0.1% formic acid (FA)/50% methanol 
solutions of each compound were individually infused into a TSQ Quantum Access triple 
quadrupole mass spectrometer (Thermo Scientific, Loughborough, UK). Collision energies for 
MS-MS were 33 V and 12 V for NH and MeNH respectively. There were three PtPI transitions 
for MeNH (m/z): 183 → 168, 183 → 140 and 183 → 115, and a single PtPI transition for THNH: 
173.1 → 144. 
 
Enzyme assay 
hNNMTWT (21.25 ng/µL) was incubated with 1 mM NH, 50 mM Tris buffer (pH 8.6) and 1 mM 
dithiothreitol (all final concentrations) in a reaction volume of 760 µL for 5 mins at 37 oC using a 
pre-heated Eppendorf heater (Grant Instruments, Shepreth, UK), after which the reaction was 
initiated by the addition of 40 µL SAM (0.5 mM final concentration). Samples (150 µL) were 
taken immediately and subsequently every 15 minutes for 45 minutes, each of which were 
immediately added to 750 µL ice-cold acetonitrile to terminate the reaction. An aliquot (100 µL) 
of the terminated reaction solution was transferred to an extraction tube. THNH internal standard 
(166 ng/mL final concentration) was added, the solution was evaporated to dryness under N2 at 
40 oC for 30 mins and then reconstituted in 200 µL 0.1% FA/50% methanol solution. The 
reconstituted solution (10 µL) was injected into a Thermo Accela Pump and Autosampler 
(Thermo Scientific) coupled to a Thermo TSQ Quantum Access, and separated using a C4 
Thermo Hypersil Gold 50x2.1 mm 1.9 µ column (Thermo Scientific) at a flow rate of 200 
µL/min using the mobile phase gradient outlined in Table S2. Eluted reaction components were 
analysed using triple quadrupole positive electrospray ionisation, with a spray voltage of 3000 
kV and a capillary temperature of 350 oC. MeNH and THNH were quantified using the peak 
areas of their respective 183 → 168 and 173.1 → 144 PtPI transitions, with confirmation of 
MeNH quantification using the 183 → 140 PtPI transition. MeNH peak area was normalised for 
THNH peak area to produce a normalised peak area (NPA) value, and MeNH production was 
calculated using a calibration curve constructed using MeNH standards of known NPA. MeNH 
production was calculated and expressed as nmol MeNH produced/mg protein. Linearity of 
reaction vs. time was determined by linear regression analysis using Prism v5.0 (GraphPad, San 
Diego, USA). Specific activity was calculated and expressed as nmoles MeNH 
produced/hour/mg protein ± SEM.  
 
Kinetic analysis of NH 2N-methyltransferase activity 
hNNMTWT was incubated as described above with 0, 0.05, 0.1, 0.25, 0.5 and 1 mM NH. Samples 
were taken at 0, 30, 60, 120, 240 and 480 secs, from which the initial velocity was calculated and 
expressed as specific activity (nmoles MeNH produced /hour/mg hNNMTWT protein). The 
kinetic constants Km  (µM ± SEM) and kcat (s-1 ± SEM) were calculated using non-linear 
Michaelis-Menten regression analysis, and were used to calculate kcat/Km which was expressed as 
s-1 M-1 ± SEM. 
 
Characterisation of NNMT and PNMT expression 
Cell culture 
SH-SY5Y human neuroblastoma cells and S.NNMT.LP (SH-SY5Y cells stably expressing a 
recombinant NNMT C-terminally fused with the V5 epitope (NNMT-V5), produced as part of 
our ongoing studies) were cultured as previously described [8]. SH-SY5Y cells were chosen due 
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to their wide use in neurotoxicity studies [37] and their lack of endogenous NNMT expression 
[8]. SH-SY5Y of passage number 19 – 22 and S.NNMT.LP of passage number 7 – 9 
(corresponding to SH-SY5Y passage number 22 – 24) were used for all experiments. 
 
Western blotting and RT-PCR analysis of NNMT and PNMT expression 
NNMT and PNMT mRNA expression in SH-SY5Y and S.NNMT.LP was assessed using RT-
PCR as previously described [8] using primers outlined in Table S3. Recombinant NNMT-V5 
and endogenous PNMT protein expression was detected using SDS-PAGE/Western blotting as 
previously described [8] using combinations of primary and secondary antibodies outlined in 
Table S1. As a positive control for PNMT expression, Balb/c mouse whole brain homogenate, 
obtained from the Biomedical Services Unit, KCL, was prepared from mice euthanized as per 
Schedule 1 of the Animal (Scientific Procedures) Act (1986) as previously described [9]. 
 
Investigation of THNH, NH and MeNH toxicity 
MTT reduction assay 
Cells were seeded into the wells of a 96-well plate in quadruplicate (Thermo Scientific, 
Loughborough, UK) at a density of 15,000 cells/well and incubated with serial dilutions of test 
compounds (THNH: 1600 – 12.5 µM; NH: 800 – 6.3 µM; MeNH: 2000 – 15.6 µM); these 
concentration ranges were optimised to ensure adequate statistics in the subsequent toxicity dose-
response data analysis. After 24, 72 and 120 h incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction was assessed as previously described [38] and 
results were calculated and expressed as percentage cell viability compared to untreated cells ± 
SEM (n = 5 for THNH and NH, n = 4 for MeNH). To calculate EC50 for each compound, 
concentration was log-transformed, and analysed using non-linear regression analysis using the 
following equation: 
 






and a constraint of y = 0 for the minimum. 
 
LDH cytotoxicity assay 
Cells were seeded and incubated with test compounds as described above for 120 h, after which 
lactate dehydrogenase (LDH) release was measured using the Pierce LDH Cytotoxicity Assay kit 
(Thermo Fisher Scientific, Paisley, UK) as per manufacturer’s instructions. LDH release was 
calculated and expressed as percentage cell death ± SEM (n = 3). Data analysis and calculation 
of LC50s was performed using non-linear regression as described above, using a constraint of y 
= 100 for the maximum. 
 
Cellular ATP content assay 
Cells were seeded into the wells of a poly-L-lysine-pretreated white 96-well plate (Greiner Bio-
One Ltd., Stonehouse, UK) at a density of 15,000 cells/well in triplicate. Cells were incubated 
with test compounds as described above for 120 h, after which ATP content was measured as 
previously described [8] and expressed as percentage ATP content compared to untreated cells ± 
SEM (n = 5 for THNH and NH, n = 4 for MeNH). Data analysis and calculation of EC50s was 
performed as described for the MTT assay.  





All statistical analysis was undertaken using Prism (Graphpad, San Diego, CA, USA). In all 
instances, significance was taken at P < 0.05. To determine the overall effect of each compound 
dose upon MTT reduction, cellular ATP content and LDH release compared to untreated cells 
for each cell line, a 1-way repeated measures ANOVA with Tukey post hoc comparisons using 
blocked, raw mean data for each experiment was performed with concentration as the 
independent variable (IV) and absorbance minus background (MTT and LDH) or luminescence 
minus background (ATP) as the dependent variable (DV) [39]. To determine cell line differences 
in toxicity for individual concentrations, a 2-way repeated measures ANOVA using blocked, 
mean data for each experiment with concentration and cell line as IV and data normalised as 
percentage of untreated cells as DV. Normalisation of the DV takes into account differences in 
baseline MTT reduction, cell death and cellular ATP differences of untreated cells between both 
cell lines [8,10]. As such, untreated cells were not included in this analysis as they would be 
expressed as 100 ± 0%. Unless otherwise stated, all P values are <0.001. To determine 
differences in compound toxicity, logEC50 or logLC50 was determined for each experimental 
repeat which were subsequently averaged to obtain logEC50s ± SEM and logLC50s ± SEM and 
have been summarised in Table S4. These were then compared using Student’s t-test 
(comparison in both cell lines) or 1-way ANOVA with Tukey post hoc comparisons (comparison 
of all three compounds or time points in a single cell line). The use of logEC50s and logLC50s, 
which follow a normal distribution, mitigates against the asymmetry that exists when the antilog 
of a log standard error is obtained [40]. 
 
RESULTS 
NNMT demonstrated norharman 2N-methyltransferase activity 
To determine whether NNMT has BC N-methyltransferase activity, we investigated whether 
recombinant hNNMTWT could N-methylate NH (Figure 2). Incubation of hNNMTWT with 1 mM 
NH resulted in the production of MeNH, which increased linearly with time (Figure 2a), 
providing a calculated specific activity of 37 ± 2 nmoles MeNH produced/hr/mg protein.  
Estimation of the kinetic parameters Km and kcat using Michaelis-Menten non-linear regression of 
enzyme incubated with varying concentrations of NH (Figure 2b) provided an estimated Km of 
90 ± 20 µM and a Kcat of 3 x 10-4 ± 2 x 10-5 s-1 respectively. kcat/Km was calculated to be 3 ± 1 s-1 
M-1. 
 
PNMT protein expression was undetectable in both SH-SY5Y and S.NNMT.LP cells 
As previously described [8], neither endogenously expressed NNMT mRNA nor recombinant 
NNMT-V5 were detected in SH-SY5Y cells, but recombinant NNMT-V5 mRNA and protein, 
however, were expressed robustly in S.NNMT.LP cells (data not shown). PNMT mRNA was 
expressed in both cell lines (Figure 3a), but PNMT protein was undetectable in either cell line 
(Figure 3b). 
 
BCs demonstrated differential toxicity towards SH-SY5Y and S.NNMT.LP cells  
Cell viability – MTT assay 
The toxicity of THNH, NH and MeNH was compared in SH-SY5Y and S.NNMT.LP after 120 h 
incubation using the MTT cell viability assay (Figure 4 and Tables 1 & 2), an early stage 
measure of toxicity [42]. THNH was significantly toxic towards SH-SY5Y cells at 400 (P < 
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0.05), 800 and 1600 µM, and towards S.NNMT.LP at the same concentrations. No significant 
difference in toxicity was observed between cell lines at any individual dose. There was no 
significant difference in EC50THNH for each cell line (P = 0.19). NH was toxic towards SH-SY5Y 
cells at 100 (P < 0.05), 200, 400 and 800 µM, and towards S.NNMT.LP at 200, 400 and 800 µM. 
No significant difference in toxicity was seen between cell lines at any individual concentration. 
There was no significant difference in EC50NH for each cell line (P = 0.78). MeNH was toxic 
towards SH-SY5Y cells at 250, 500, 1000 and 2000 µM. MeNH demonstrated toxicity towards 
S.NNMT.LP at 500, 1000 and 2000 µM, and increased cell viability at 62.5 and 125 µM. There 
was a significant difference in toxicity towards SH-SY5Y and S.NNMT.LP at 125 µM (93 ± 3% 
vs. 164 ± 7%) and 250 µM (55 ± 2% vs. 92 ± 6%, P < 0.01). The EC50MeNH was significantly 
lower in SH-SY5Y than S.NNMT.LP (P = 0.009). 
 
For SH-SY5Y cells (Figure S1), there were significant differences in the EC50s for all 
compounds, with EC50THNH greater than both EC50NH and EC50MeNH. Likewise, EC50MeNH was 
significantly greater than EC50NH. For S.NNMT.LP cells (Figure S1), EC50THNH was 
significantly greater than EC50NH, and EC50MeNH was greater than EC50NH. In contrast, 
EC50THNH was not significantly different to EC50MeNH. 
 
Cell death – LDH release 
We next investigated the effect of BCs upon cell death after 120 h incubation as measured by the 
LDH assay (Figure 5 and Tables 1 & 2), an end stage measure of toxicity [41]. THNH was toxic 
towards both SH-SY5Y and S.NNMT.LP cells at 1600 µM only. THNH was significantly more 
toxic towards SH-SY5Y than S.NNMT.LP cells at 400 µM (27 ± 3% vs. 13 ± 0.6%) and 1600 
µM (58 ± 10% vs. 34 ± 2%). There was no significant difference in LC50THNH for each cell line 
(P = 0.12). NH was toxic towards both SH-SY5Y and S.NNMT.LP cells at 200, 400 and 800 
µM. Cell death was significantly higher in SH-SY5Y compared to S.NNMT.LP cells at 400 µM 
(85 ± 6% vs. 54 ± 0.6%). The LC50NH was significantly lower in SH-SY5Y compared to 
S.NNMT.LP (P = 0.0006). MeNH was toxic towards SH-SY5Y cells at 2000 µM only, whereas 
MeNH was toxic towards S.NNMT.LP cells at 500, 1000 and 2000 µM. Cell death was 
significantly lower in SH-SY5Y compared to S.NNMT.LP cells at 500 µM (34 ± 2% vs. 99 ± 
3%), 1000 µM (31 ± 6% vs. 84 ± 4%) and 2000 µM (73 ± 2% vs. 89 ± 5%). The LC50MeNH was 
significantly higher in SH-SY5Y compared to S.NNMT.LP cells (P = 0.0002). 
 
For SH-SY5Y (Figure S2), the LC50NH was significantly lower than both the LC50THNH and 
LC50MeNH, with no significant difference between LC50THNH and LC50MeNH. In contrast, for 
S.NNMT.LP cells (Figure S2) LC50THNH was significantly greater than both LC50NH and 
LC50MeNH. There was no significant difference between LC50NH and LC50MeNH. 
 
Cellular ATP content assay 
The effect of BCs upon cellular ATP content after 120 h incubation was assessed (Figure 6 and 
Tables 1 & 2). THNH reduced cellular ATP content in SH-SY5Y cells at 400, 800 and 1600 µM. 
Likewise, THNH reduced cellular ATP content in S.NNMT.LP cells at the same concentrations. 
No significant difference in cellular ATP content was observed between cell lines at any 
individual dose. There was no significant difference in EC50THNH for each cell line (P = 0.21). 
NH reduced cellular ATP content in SH-SY5Y cells at 400 and 800 µM, whereas in 
S.NNMT.LP NH reduced cellular ATP content at 200, 400 and 800 µM. There was a significant 
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difference in cellular ATP content in SH-SY5Y and S.NNMT.LP at 200 µM (86 ± 15% vs. 39 ± 
5%). The EC50NH was significantly higher in SH-SY5Y compared with S.NNMT.LP cells (P = 
0.02). MeNH reduced cellular ATP content in SH-SY5Y cells at 250, 500, 1000 and 2000 µM. 
In S.NNMT.LP, MeNH reduced cellular ATP content at 500, 1000 and 2000 µM, and increased 
cellular ATP content at 125 µM (P < 0.05). Cellular ATP content was significantly lower in SH-
SY5Y than S.NNMT.LP at 125 µM (74 ± 9% vs. 140 ± 14%) and 250 µM (46 ± 16% vs. 110 ± 
11%). The EC50MeNH was significantly lower in SH-SY5Y compared with S.NNMT.LP cells (P 
= 0.009). 
 
For SH-SY5Y (Figure S3), the EC50THNH was significantly greater than both EC50NH and 
EC50MeNH, with no difference between EC50NH and EC50MeNH. For S.NNMT.LP (Figure S3), the 
EC50THNH was greater than EC50NH, as was EC50MeNH compared to EC50NH.  In contrast, the 
EC50THNH was not significantly different to EC50MeNH.  
 
Effect of length of exposure upon cell viability 
Finally, we investigated whether BCs demonstrated time-dependent differences in cell viability 
as measured using the MTT reduction assay (Figure 7 and Tables 1 & 2). THNH was toxic 
towards SH-SY5Y cells after 24 h incubation at 400, 800 and 1600 µM. Likewise, after 72 h 
incubation THNH was toxic at the same concentrations. THNH was toxic towards S.NMT.LP 
cells after 24 h incubation at concentrations of 200 µM and greater. After 72 h incubation, 
THNH was significantly toxic at concentrations of 400, 800 and 1600 µM. THNH did not 
increase MTT reduction at any concentration or time point in either cell line. There was no 
significant difference in EC50THNH towards both SH-SY5Y and S.NNMT.LP cells over the time 
course of the experiment. There were no significant differences in EC50THNH at each time point 
between SH-SY5Y and S.NNMT.LP cells.  
 
NH was toxic towards SH-SY5Y cells after 24 h incubation at 100 (P < 0.01), 200, 400 and 800 
µM. After 72 h incubation, NH was toxic at the same concentrations. Likewise, NH was toxic 
towards S.NNMT.LP cells after 24 h incubation at concentrations of 100 µM and greater. After 
72 h incubation, NH was toxic at 200 (P < 0.01), 400 and 800 µM. NH did not increase MTT 
reduction at any concentration or time point in either cell line. There were no significant 
differences in EC50NH towards both cell lines over the time course of the experiment. There was 
no significant difference in EC50NH at each time point between SH-SY5Y and S.NNMT.LP.  
 
MeNH was toxic towards SH-SY5Y cells after 24 h incubation at 500 (P < 0.01), 1000 and 2000 
µM. After 72 h incubation, MeNH was toxic at 1000 and 2000 µM. MeNH was toxic towards 
S.NNMT.LP cells after 24 h incubation at 500, 1000 and 2000 µM. After 72 h incubation, 
MeNH was toxic at 1000 and 2000 µM. MeNH did not increase MTT reduction in SH-SY5Y at 
any of the concentrations or time points investigated, however MTT reduction was increased in 
S.NNMT.LP after 72 h incubation with 31.3 and 62.5 µM (P < 0.05) MeNH. There were 
significant differences in EC50MeNH over the time course of the experiment. In SH-SY5Y cells, 
EC50MeNH decreased with increasing length of incubation. In S.NNMT.LP cells, EC50MeNH was 
not significantly different after 24 and 72 h incubation, however EC50MeNH was significantly 
lower after 120 h incubation (P < 0.05). After 24 h incubation, MeNH was significantly less 
toxic towards SH-SY5Y than S.NNMT cells (P = 0.006), however due to the increasing toxicity 
of MeNH towards SH-SY5Y with increasing length of incubation, there was no significant 
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difference in EC50MeNH observed between SH-SY5Y and S.NNMT.LP cells after 72 h 
incubation and was significantly more toxic towards SH-SY5Y than S.NNMT.LP after 120 h 
incubation (P = 0.008).  
 
In SH-SY5Y cells after 24 h incubation, EC50MeNH was greater than both EC50THNH (P < 0.01) 
and EC50NH, with EC50THNH greater than ECNH (P < 0.01). Likewise, after 72 h incubation, 
EC50MeNH was greater than both EC50THNH (P < 0.05) and EC50NH (P < 0.01), with EC50THNH 
greater than ECNH (P < 0.05). In S.NNMT.LP cells after 24 h incubation, there was no significant 
difference between EC50MeNH and EC50THNH, whereas both EC50THNH and EC50MeNH were 
significantly greater than EC50NH (P < 0.01 for both).  After 72 h incubation, there was no 
significant difference between EC50THNH and EC50NH, whereas both EC50THNH and EC50NH 
were lower than EC50MeNH.  
 
DISCUSSION 
The potential for NNMT to N-methylate endogenously and exogenously-derived compounds 
such as BCs into inhibitors of CxI been proposed previously [2,7,12] but has not been 
demonstrated hitherto. This study is the first to demonstrate that (1) NNMT has NH 2N-
methyltransferase activity and (2) MeNH is less toxic than NH.   
 
NNMT demonstrated norharman 2N-methyltransferase activity 
The demonstration of NH 2N-methyltransferase activity for NNMT (Figure 2) is the first direct 
experimental evidence of such towards an endogenously-produced substrate other than 
nicotinamide, and is a further addition to the list of pyridine-containing compounds which are 
substrates for NNMT [32]. Comparison of the kinetic parameters for NNMT reveals that NNMT 
has a lower Km yet lower kcat and kcat/Km towards NH compared to nicotinamide. Our own studies 
of human NNMT, using whole liver homogenate as source, reported a Km of 1.36 mM for 
nicotinamide, 15-times higher than that for NH reported here [36]. Studies by Rini et al. [42] of 
human liver NNMT demonstrated a similar trend, with a Km of 350 µM (4-times higher). We 
have previously reported a Km of 380 – 430 µM for the hNNMTWT used in this study [35], 4.4 – 
4.9-fold higher than the Km for NH. The kcat for NH is 265-fold lower than that for nicotinamide 
[35]. Such a low kcat is not without precedence. The DNA endonuclease I-Crel and γ-secretase 
have very low catalytic turnover towards their endogenous substrates, as evidenced by kcat values 
of 4 x 10-4 s-1 and 1.2 x 10-3 s-1 respectively [43,44]. Furthermore, the amino acid transaminase 
activity of tyrosine phenol-lyase is similar to that which we report for the N-methylation of NH, 
with kcat in the range 1 x 10-4 – 2 x 10-3 s-1 dependent upon substrate [45]. Such a low kcat 
indicates that the Km for the N-methylation of NH is close to ks, the equilibrium dissociation 
constant for the NNMT-NH complex, suggesting that NH is not a good substrate for NNMT. 
This is supported by comparing kcat/Km of NNMT for NH with that of nicotinamide, which is 54-
fold larger [35]. Thus, it is clear that nicotinamide is the preferred substrate for the enzyme and, 
within the cell, NH metabolism may be inhibited by nicotinamide via competitive inhibition. The 
rate at which BCs are endogenously produced is unknown, although it is likely that both BC and 
nicotinamide levels will fluctuate due to dietary intake [46]. Hence, it is not possible to state with 
certainty that the intracellular concentrations of nicotinamide will be in excess of NH at all 
times; therefore, whilst NNMT can N-methylate NH, the degree to which this occurs in the cell is 
uncertain.    
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In contrast to what we have previously observed for nicotinamide, NNMT does not appear to 
demonstrate substrate inhibition kinetics when incubated with NH (Figure 2B) [36]. This may 
arise due to the differences in NNMT preparation used in the respective studies, i.e. whole liver 
homogenate vs. purified recombinant protein. Also, it is possible that incubation with higher 
concentrations of NH may yet reveal substrate inhibition. Nonetheless, these results do suggest 
differing regulation of NNMT’s various enzyme kinetic activities which may reflect their 
respective metabolic requirements. 
 
The expression of NNMT-V5 influenced the toxicity of BCs 
No study has investigated the effect of the expression of an enzyme known to possess BC N-
methyltransferase activity upon their toxicities. In our present study, THNH – the precursor of 
NH – was the least toxic of all three compounds investigated, and its overall toxicity (as 
measured using EC50s and LC50) was not influenced by the expression of NNMT-V5 (Figures 4 
– 7). Tetrahydro-BC alkaloids such as THNH and 1-methyl-THNH carboxylate occur in foods 
such as wine, seasonings and fruit products, and possess radical scavenging properties [47]. 
Injection of 2-N-methyl-THNH, the aliphatic analogue of MeNH, into rat brain has no effect on 
dopaminergic neurone viability or function [48], which taken together with our results 
demonstrate that the pyridinium moiety is essential for BC toxicity.  
 
In contrast, NNMT-V5 expression influenced the toxicity of NH. The EC50ATP for NH was 
lower in S.NNMT.LP compared to that of SH-SY5Y cells (Figure 5), possibly due to the 
increased N-methylation of NH in S.NNMT.LP cells by NNMT-V5. This N-methylation most 
likely occurs via NNMT-V5 as evidenced by the lack of PNMT expression in either cell line. 
Since MeNH is a weak CxI inhibitor, although with a 7-fold higher IC50 than MPP+, it is also 
possible that the increased toxicity of NH (in terms of reduction in cellular ATP concentration) 
in S.NNMT.LP cells may arise due to its inhibition of Complex III [11]. Conceivably, this 
inhibitory effect would be greater in S.NNMT.LP cells as the rate of oxidative phosphorylation is 
increased compared to that in SH-SY5Y cells [8]. NH toxicity, however, is thought to be 
mediated predominantly via the formation of DMeNH [22], making the inhibition of Complex III 
by NH unlikely to be responsible for the effect observed.  
 
Of significance was the observation that the EC50NH for cell viability (as measured using the 
MTT assay, Figure 7) towards each cell line after 120 h incubation was not significantly 
different, whereas its LC50
 
after 120 h incubation (Figure 5) was higher in S.NNMT.LP cells, 
demonstrating that the decrease in cellular ATP content observed in S.NNMT.LP (Figure 6) was 
not cytotoxic and that NNMT-V5 expression protected against NH-induced cell death. It is 
possible that the deleterious effects of NH on cell viability were not manifest over the time 
period of the experiment, hence prolonged incubation with NH may result in decreased cell 
viability and increased cell death being observed. In mitigation of this, the EC50MTT for NH over 
the 120 h of the experiment (Figure 4) did not decrease; as such it is unlikely that further 
prolonged incubation would result in an increase in toxicity. It is possible that, although cell 
viability was not compromised, the reduction in cellular ATP in response to NH may leave the 
cell susceptible to further cytotoxic challenge, resulting in an eventual reduction in cell death.  
 
MeNH was less toxic than NH towards both SH-SY5Y and S.NNMT.LP cells (Figures 4 & 6). 
This contrasts with findings from other studies which suggest that MeNH is more toxic than NH 
NNMT and norharman metabolism 
12 
 
[20,21,23]. There are a number of potential explanations for this observation. The first is that 
MeNH, as a charged molecule, was unable to enter the cell to elicit toxicity. This is supported by 
studies using HEK293 cells overexpressing DAT, which reported that the toxicity of MeNH 
relied upon DAT expression [23]. In contrast, NH would enter the cell via passive diffusion due 
to its relatively high lipophilicity (logP = 3.17). Renal stem cell-derived HEK293 cells do not 
endogenously express DAT [49] and may thus demonstrate differing susceptibilities to BCs and 
their methylated forms compared to neuronally-derived cells. Furthermore, the DAT-containing 
plasmid used in Wernicke’s study was a CMV promoter-based plasmid which, in HEK293 cells, 
would result in robust levels of protein expression [50], potentially resulting in 
supraphysiological levels of protein expression and so exaggerate the toxicity of MeNH. Storch 
and colleagues [51], using the same HEK293 model, demonstrated that there was no correlation 
between the Vmax of uptake kinetics of BCs and their cytotoxicity, nor was there a correlation 
between cytotoxicity and lipophilicity. In support of our observations, SH-SY5Y cells in their 
undifferentiated state express DAT [52,53] and as such are able to transport MeNH into the cell. 
Due to its positively charged nature, MeNH would sequester into the mitochondrion, raising the 
local concentration significantly [54]. Finally, many of the in vivo studies of BC toxicity use 
supraphysiological, acutely-administered concentrations of BC which do not mirror the gradual 
production and sequestering of MeNH modelled in our study. 
 
The NNMT-V5-mediated protection against MeNH-induced reduction in cell viability and 
cellular ATP concentration in S.NNMT.LP cells after 120 h incubation (Figures 4 & 6) is in 
accord with our previous studies which have demonstrated similar protection against other CxI 
inhibitors [8,10]. More significant was the dose-dependent increase in cell viability and cellular 
ATP concentration in S.NNMT.LP by low concentrations of MeNH, an effect which was only 
manifest after 72 h incubation and which was not observed with either THNH or NH (Figures 6 
& 7). This delayed increase in mitochondrial function may be an adaptive response of the cell to 
sub-lethal cytotoxic challenge. The mechanisms underlying this cytoprotection are as yet 
unknown, although the activation of the neuroprotective Akt signalling pathway in S.NNMT.LP 
[9] is an example of one such possibility. What is of note is that NNMT-V5 expression in 
S.NNMT.LP did not significantly increase MeNH’s LC50 compared to that of NH, which is in 
contrast to both the EC50MTT and EC50ATP and was not observed in SH-SY5Y cells (Figure 5). 
The LC50 for MeNH was also significantly higher in SH-SY5Y compared to S.NNMT.LP. The 
reasons for these differences are unclear, however it does suggest that the toxicity of MeNH may 
not solely be mediated via CxI inhibition but may involve as-yet unidentified mechanism(s) 
which are specific to NNMT-expressing cells.  
 
NNMT may be a detoxification pathway for β-carbolines 
This use of SH-SY5Y cells in PD-relevant neurotoxicity studies is controversial. Although 
widely used for studies such as ours [37], SH-SY5Y are pan-neuronal in their phenotype [9] and 
are tumorigenic in nature [55,56]. Nevertheless, undifferentiated SH-SY5Y cell do demonstrate 
some neuronal characteristics such as the expression of the presynaptic marker synaptophysin, 
the accumulation and release of dopamine and the expression of DAT [9,52,53]. Consequently, 
many studies use retinoic acid-based protocols to produce terminally-differentiated dopaminergic 
neurones [55-57], in which a number of proteins and signalling pathways are induced, for 
example Akt, which may affect toxicity. In both SH-SY5Y cell and PD animal models Akt 
induction has been shown to confer neuroprotection against the toxicity of the classic PD 
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neurotoxin 6-hydroxydopamine [52,58]. It is also unknown as to what effect differentiation has 
upon the expression of N-methyltransferases capable of N-methylating BCs. Thus, differentiation 
may mask the effects of NNMT-V5 upon BC toxicity that we wish to observe. The benefit of 
using the combination of SH-SY5Y and S.NNMT.LP is that they provide us with a true knock-
in/knock-out model of NNMT expression and is ideal for the investigation of how NNMT 
influences the toxicity of BCs. Finally, the expression of NNMT-V5 in N27 rat mesencephalic 
neurones, an immortalised dopaminergic phenotype cell line, reproduced the effects of NNMT-
V5 expression in SH-SY5Y [9], suggesting that many of the effects of NNMT-V5 expression in 
SH-SY5Y are likely to be replicated in neurones. 
 
The observations that NNMT.V5-expressing cells are protected from NH-induced cell death, 
MeNH-induced reduction in cell viability and cellular ATP content, and that MeNH is less toxic 
than NH towards both cell lines suggests that NNMT may serve as a detoxification mechanism 
for BCs. There are caveats to this. Firstly, NH is a much poorer substrate than nicotinamide. 
Second, MeNH can be further converted to the more toxic species DMeNH. The enzyme 
responsible for this is unlikely to be NNMT for two reasons: (1) the lack of increase in toxicity 
observed for MeNH in S.NNMT.LP cells compared to SH-SY5Y, and (2) the lack of reports in 
the literature demonstrating that NNMT can N-methylate aliphatic nitrogen atoms. Therefore, 
confirmation of NNMT’s detoxification of NH using pathophysiologically-relevant in vivo 
models will strengthen the evidence for a detoxification role for NNMT in the brain and confirm 
NNMT’s central role in the regulation of cellular function and survival. 
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THNH NH MeNH 
SH-SY5Y S.NNMT.LP SH-SY5Y S.NNMT.LP SH-SY5Y S.NNMT.LP 
EC5024 5481 
(523 ± 42)2 
521 
(528 ± 23) 
221 
(221 ± 16) 
199 
(188 ± 14) 
1370 
(1389 ± 84) 
759 
(770 ± 8) 
EC5072 454 
(474 ± 10) 
327 
(331 ± 6) 
223 
(228 ± 25) 
288 
(294 ± 18) 
869 
(881 ± 20) 
619 
(650 ± 36) 
EC50120 429 
(432 ± 21) 
366  
(374 ± 31) 
158 
(162 ± 18)  
155 
(159 ± 18)  
257 
(237 ± 28) 
355 
(322 ± 21) 
LC50 1880 
(2068 ± 38) 
2430 
(2352 ± 52) 
269 
(270 ± 18) 
406 
(404 ± 10) 
1830 
(1820 ± 86) 
355 
(362 ± 48) 
EC50ATP 437 
(452 ± 80) 
348 
(335 ± 37) 
263 
(291 ± 41) 
174 
(225 ± 52) 
260 
(247 ± 56) 
356 
(383 ± 29) 
 
Table 1. Summary of EC50 and LC50 values for 1,2,3,4-tetrahydronorharman (THNH), 
norharman (NH) and 2-N-methylnorharman (MeNH). 1Values are the antilog of logEC50 or 
logLC50 values shown in Supplementary Table S4 and are expressed as µM. 2Values in brackets 
are the average of EC50 or LC50 values obtained from each experimental replicate and are 
expressed as µM ± SEM. All values are the average of 3 – 5 experiments. Statistical analysis was 
performed using the logEC50 and logLC50 ± SEM values shown in Supplementary Table S4.






12.5 25 50 100 200 400 800 1600 
MTT 24 h  SH-SY5Y - - - - - 57 ± 6 16 ± 1 7 ± 2 
S.NNMT.LP - - - - 89 ± 3* 85 ± 7 8 ± 0.7 4 ± 2 
MTT 72 h  SH-SY5Y - - - - - 47 ± 3 32 ± 3 19 ± 1 
S.NNMT.LP - - - - - 30 ± 3 4 ± 2 1 ± 1 
MTT 120 h SH-SY5Y - - - - - 66 ± 15* -0.4 ± 0.2 -0.9 ± 0.1 
S.NNMT.LP - - - - - 42 ± 13 -0.7 ± 0.3 -0.7 ± 0.4 
LDH SH-SY5Y - - - - - - - 58 ± 10 
S.NNMT.LP - - - - - - - 34 ± 2 
ATP SH-SY5Y - - - - - 33 ± 13 4 ± 3 0.4 ± 0.4 





6.3 12.5 25 50 100 200 400 800 
MTT 24 h  SH-SY5Y - - - - 82 ± 3** 60 ± 2 13 ± 3 0.1 ± 0.2 
S.NNMT.LP - - - - 87 ± 5 51 ± 7 8 ± 2 0.3 ± 0.1 
MTT 72 h  SH-SY5Y - - - - 73 ± 4 60 ± 7 10 ± 3 1 ± 0.2 
S.NNMT.LP - - - - - 76 ± 7** 24 ± 3 7 ± 0.7 
MTT 120 h SH-SY5Y - - - - 79 ± 8* 35 ± 13 -0.8 ± 0.1 -0.6 ± 0.3 
S.NNMT.LP - - - - - 30 ± 10 -0.7 ± 0.2 -1 ± 0.2 
LDH SH-SY5Y - - - - - 39 ± 2 85 ± 6 94 ± 3 
S.NNMT.LP - - - - - 33 ± 2 54 ± 0.6 100 ± 0.4 
ATP SH-SY5Y - - - - - - 2 ± 1 -0.1 ± 0.2 





15.6 31.3 62.5 125 250 500 1000 2000 
MTT 24 h  SH-SY5Y - - - - - 79 ± 2** 65 ± 0.8 20 ± 8 
S.NNMT.LP - - - - - 52 ± 2 18 ± 4 4 ± 3 
MTT 72 h  SH-SY5Y - - - - - - 55 ± 3 0.2 ± 1 
S.NNMT.LP - 130 ± 10 120 ± 7* - - - 6 ± 0.2 0.7 ± 0.4 
NNMT and norharman metabolism 
20 
 
MTT 120 h SH-SY5Y - - - - 55 ± 2 11 ± 3 0.1 ± 0.2 -0.04 ± 0.1 
S.NNMT.LP - - 143 ± 4 164 ± 7 - 22 ± 8 0 ± 0.1 -0.04 ± 0.1 
LDH SH-SY5Y - - - - - - - 73 ± 2 
S.NNMT.LP - - - - - 99 ± 3 84 ± 4 89 ± 5 
ATP SH-SY5Y - - - - 46 ± 16 7 ± 4 0 ± 0.01 -0.4 ± 0.4 
S.NNMT.LP - - - 140 ± 14* - 17 ± 4 0 ± 0.01 0 ± 0.01 
 
Table 2 Summary of significant changes in cell viability (MTT), cell death (LDH) and intracellular ATP concentrations (ATP) in SH-
SY5Y and S.NNMT.LP cells. For MTT and ATP experiments, results are expressed as percentage of untreated cells ± SEM. For LDH 
experiments, results are expressed as percentage cell death ± SEM. Only statistically significant results are shown and all are P < 
0.001 unless otherwise indicated: * = P < 0.05, ** = P < 0.01. 
  





Figure 1. Metabolic pathways of the β-carboline norharman and the structural similarity of 
2-methylnorharman to MPP+. Both compounds possess the same basic aromatic benzene and 
pyridine rings structure, with the addition of a bridging secondary amine between the two rings 
of 2-methylnorharman. SAM: S-adenosylmethionine, SAH: S-adenosylhomocysteine, [O]: 
oxidation. 
  




Figure 2. Biochemical analysis of norharman 2N-methyltransferase activity using a 
modified NNMT enzyme activity assay. Norharman was used as substrate, with detection of 2-
N-methylnorharman performed using mass spectrometry. (A) Linearity of 2-N-methylhorharman 
production with time. (B) Non-linear regression analysis of norharman 2N-methyltransferase 
activity using Michaelis-Menten kinetic analysis. Specific activity is expressed as nmoles 2-N-
methylhorharman produced/hour/mg hNNMTWT protein. 
  





Figure 3. PNMT expression in SH-SY5Y and S.NNMT.LP cells. (A) Analysis of PNMT 
mRNA expression in SH-SY5Y and S.NNMT.LP cells using RT-PCR. (B) Analysis of PNNMT 
protein expression in whole mouse brain homogenate, SH-SY5Y and S.NNMT.LP cells using 
Western blotting. Bp: 100 bp ladder, Ctrl: no template control. 
  





Figure 4. Toxicity of 1,2,3,4-tetrahydronorharman (THNH), norharman (NH) and 2-N-
methylnorharman (MeNH) towards SH-SY5Y and S.NNMT.LP cells using the MTT 
reduction assay. Cell viability was expressed as percentage of untreated cells ± SEM (n = 5 for 
THNH and NH, n = 4 for MeNH). Curve fitting was undertaken using non-linear regression 
analysis. Statistical analysis of individual dose toxicity between cell lines consisted of two-way 
repeated measures ANOVA: ** = P < 0.01, *** = P < 0.001. Solid black line = SH-SY5Y, 
dashed red line = S.NNMT.LP.  
  





Figure 5. Effect of 1,2,3,4-tetrahydronorharman (THNH), norharman (NH) and 2-N-
methylnorharman (MeNH) upon cell death using the LDH cytotoxicity assay. Cell death 
was expressed as percentage cell death ± SEM (n = 3 for all). Curve fitting was undertaken using 
non-linear regression analysis. Statistical analysis of individual dose toxicity between cell lines 
consisted of two-way repeated measures ANOVA: * = P < 0.05, *** = P < 0.001. Solid black line 
= SH-SY5Y, dashed red line = S.NNMT.LP.  
  





Figure 6. Effect of 1,2,3,4-tetrahydronorharman (THNH), norharman (NH) and 2-N-
methylnorharman (MeNH) upon cellular ATP content in SH-SY5Y and S.NNMT.LP cells. 
Cellular ATP content was expressed as percentage of untreated cells ± SEM (n = 5 for THNH 
and NH, n = 4 for MeNH). Curve fitting was undertaken using non-linear regression analysis. 
Statistical analysis of individual dose toxicity between cell lines consisted of two-way repeated 
measures ANOVA: ** = P < 0.01, *** = P < 0.001. Solid black line = SH-SY5Y, dashed red line 
= S.NNMT.LP. Cellular ATP content in untreated cells: SH-SY5Y = 150 ± 12 pmoles/mg 
protein, S.NNMT.LP = 310 ± 54 pmoles/mg protein. 
 
  





Figure 7. Effect of length of incubation with 1,2,3,4-tetrahydronorharman (THNH, left 
hand panels), norharman (NH, middle panels) and 2-N-methylnorharman (MeNH, right 
hand panels) upon cell viability measured using the MTT reduction assay, and 
comparisons of EC50s, in SH-SY5Y (top three panels) and S.NNMT.LP (bottom three 
panels) cell lines. Cell viability was expressed as percentage of untreated cells ± SEM (n = 4 for 
NH and MeNH, n = 3 for THNH). For all panels: solid black line = 24 h, large dashed red line = 
72 h, small dashed green line = 120 h. 
 
 
 
